Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV) announced SkinMedica's reimagined packaging and the new HA5® Hydra Collagen Water Burst Moisturizer on Oct 9, 2025. The redesign features a refreshed logo, luxe copper accents, intuitive navigation, and sustainability upgrades: 90% of packaging components by weight recyclable, 100% of secondary cartons recyclable, and a 71% reduction in landfill waste (~550,000 lbs annually). Product launches include HA5 moisturizer (up to 24-hour hydration, 25% moisture boost after one application), TNS Advanced+ serum dual-pump, and phased rollout across the portfolio over the next year. HA5 moisturizer retails at $78 and is available online and via licensed physicians and spas.
AbbVie (NYSE: ABBV) reported positive topline results from the Phase 2 ELATE trial of onabotulinumtoxinA (BOTOX) for upper limb essential tremor on Oct 6, 2025. The study met its primary endpoint at week 18: TREDS-R total unilateral score change was -2.61 for onabotulinumtoxinA vs -1.61 for placebo (p=0.029). The trial also met all six secondary endpoints. Safety was consistent with the known profile of onabotulinumtoxinA; the most common adverse event was localized, mostly mild-to-moderate muscular weakness (24.5% on active vs 2.3% placebo). Results will be presented at the International Congress of Parkinson's Disease and Movement Disorders on Oct 8, 2025. BOTOX for essential tremor is not approved by the FDA or other regulators.
AbbVie (NYSE:ABBV) has scheduled its third-quarter 2025 financial results announcement for Friday, October 31, 2025, before market opening. The company will conduct a live earnings conference call at 8 a.m. Central time.
Investors can access the webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived version of the presentation will be made available later the same day.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has secured a supplier agreement with Vizient, Inc., the largest provider-driven healthcare performance improvement company in the U.S. The agreement provides Vizient's network, which represents over 50% of U.S. healthcare organizations, enhanced access to Natrelle®'s comprehensive breast implant line featuring more than 300 implant options.
The partnership offers Vizient clients competitive pricing, simplified procurement, improved operational efficiency, and direct support from Natrelle®'s sales and technical teams. Natrelle®, currently the #1 selected breast implant by plastic surgeons, brings a 50-year legacy of excellence in breast reconstruction and augmentation solutions.
AbbVie (NYSE:ABBV) has initiated construction on a $70 million expansion at its AbbVie Bioresearch Center in Worcester, Massachusetts. The expansion is part of AbbVie's broader $10 billion U.S. investment commitment to enhance biologics manufacturing capabilities and capacity.
The project includes new biologics manufacturing areas and a three-story building for laboratory, warehouse, and office space. This investment will facilitate the transfer of select oncology products from Europe to the U.S. and support the production of current and next-generation oncology and immunology medicines. The expansion will create new jobs, adding to AbbVie's existing 28,000 U.S. employees, including over 2,000 in Massachusetts.
AbbVie (NYSE:ABBV) has submitted a Biologics License Application (BLA) to the FDA for Pivekimab sunirine (PVEK), a novel CD123-targeting antibody-drug conjugate designed to treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare and aggressive blood cancer.
The BLA submission is supported by data from the Phase 1/2 CADENZA trial, which evaluated PVEK's safety and efficacy in BPDCN patients. This represents AbbVie's first ADC development in blood cancer, targeting the CD123 protein that is overexpressed in BPDCN cells.
BPDCN typically manifests with skin lesions and can spread to bone marrow, central nervous system, and lymph nodes. Current treatment options are limited to intensive chemotherapy and stem cell transplant, highlighting the urgent need for innovative therapies.
AbbVie (NYSE: ABBV) has commenced construction of a new active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois. The $195 million investment is part of AbbVie's broader $10 billion capital investment plan over the next decade to enhance U.S. manufacturing capabilities.
The facility, expected to be fully operational by 2027, will focus on producing API components for immunology, oncology, and neuroscience medicines. This strategic move will relocate select API production from Europe and Asia to the U.S. The project will create new jobs, adding to AbbVie's existing workforce of 28,000 U.S. employees across all 50 states and Puerto Rico, including 6,000 jobs at 11 manufacturing sites.
AbbVie (NYSE:ABBV) has announced its pricing strategy for ELAHERE® (mirvetuximab soravtansine-gynx) in the UK, setting the list price equal to US levels. ELAHERE is the first-and-only approved FRα-directed antibody drug conjugate (ADC) for treating platinum-resistant ovarian cancer patients who have received 1-3 prior treatments.
The company is currently in discussions with NICE to ensure fair valuation of ELAHERE, which represents the first new treatment in 10 years for platinum-resistant ovarian cancer in the UK. The drug received MHRA approval in July 2025, following FDA approval in March 2024 and European Commission approval in November 2024.
AbbVie (NYSE:ABBV) has submitted a New Drug Application (NDA) to the FDA for tavapadon, a novel once-daily oral treatment for Parkinson's disease. The submission is supported by positive results from the Phase 3 TEMPO clinical program, which demonstrated significant efficacy across multiple trials.
The TEMPO program included three Phase 3 trials: TEMPO-1 and TEMPO-2 showed statistically significant improvement in MDS-UPDRS Parts II and III scores in early Parkinson's patients, while TEMPO-3 demonstrated increased "on" time in patients using tavapadon as an adjunctive therapy to levodopa. The submission also includes interim data from the TEMPO-4 open-label extension trial.
Allergan Aesthetics (NYSE:ABBV) will showcase its new AA Signature™ multimodal treatment approach at the AMWC Dubai conference from October 1-3, 2025. The approach, already successfully launched in 25 countries, addresses different patient needs including Lift Up, Distinct Definition, and skin quality improvement.
The company will host two major symposiums: an AMI symposium featuring Dr. Mauricio de Maio demonstrating live injections, and a Global Medical Affairs symposium focused on skin quality multimodal mastery. Additionally, 7 e-posters presenting new clinical data will be featured at the conference, covering topics from personalized aesthetics to skin quality treatments.